ZA200301082B - Quinazoline derivatives as alpha-1 adrenergic antagonists. - Google Patents

Quinazoline derivatives as alpha-1 adrenergic antagonists. Download PDF

Info

Publication number
ZA200301082B
ZA200301082B ZA200301082A ZA200301082A ZA200301082B ZA 200301082 B ZA200301082 B ZA 200301082B ZA 200301082 A ZA200301082 A ZA 200301082A ZA 200301082 A ZA200301082 A ZA 200301082A ZA 200301082 B ZA200301082 B ZA 200301082B
Authority
ZA
South Africa
Prior art keywords
methyl
amino
phenyl
compound
dimethoxy
Prior art date
Application number
ZA200301082A
Other languages
English (en)
Inventor
Cyrus Kephra Becker
Juerg Roland Pfister
Chris Richard Melville
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200301082B publication Critical patent/ZA200301082B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200301082A 2000-08-31 2003-02-07 Quinazoline derivatives as alpha-1 adrenergic antagonists. ZA200301082B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
ZA200301082B true ZA200301082B (en) 2004-05-07

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301082A ZA200301082B (en) 2000-08-31 2003-02-07 Quinazoline derivatives as alpha-1 adrenergic antagonists.

Country Status (19)

Country Link
US (1) US6559153B2 (fr)
EP (1) EP1315714B1 (fr)
JP (1) JP3971299B2 (fr)
KR (1) KR100602929B1 (fr)
CN (1) CN1308324C (fr)
AR (1) AR032475A1 (fr)
AT (1) ATE309240T1 (fr)
AU (2) AU9378801A (fr)
BR (1) BR0113585A (fr)
CA (1) CA2420177C (fr)
DE (1) DE60114852T2 (fr)
ES (1) ES2251512T3 (fr)
GT (1) GT200100181A (fr)
MX (1) MXPA03001777A (fr)
PA (1) PA8527901A1 (fr)
PE (1) PE20020407A1 (fr)
UY (1) UY26919A1 (fr)
WO (1) WO2002018348A2 (fr)
ZA (1) ZA200301082B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423392B1 (fr) 2001-08-10 2006-10-04 Neuro Therapeutics Limited Derives de composes opioides du type morphine
EP1490338B1 (fr) * 2002-04-03 2011-08-24 Orion Corporation Utilisation de l'antagoniste d'un alfa2-adrenocepteur en cas de maladies du snc
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
WO2004111014A1 (fr) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp
KR100977242B1 (ko) * 2003-07-24 2010-08-24 유로-셀띠끄 소시에떼 아노님 피페리딘 화합물 및 그들을 포함하는 약학적 조성물
WO2006021345A2 (fr) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics et therapeutiques pour des maladies associees au recepteur alpha-1b adrenergique (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
JP4796624B2 (ja) 2005-05-04 2011-10-19 エフ.ホフマン−ラ ロシュ アーゲー 5−ht受容体に作用する(3,4−ジヒドロ−キナゾリン−2−イル)−(2−アリールオキシ−エチル)−アミン類
EP2043655A2 (fr) 2006-04-25 2009-04-08 Astex Therapeutics Limited Derives de purine et de deazapurine comme composes pharmaceutiques
JP5144666B2 (ja) * 2006-09-19 2013-02-13 スリーエム イノベイティブ プロパティズ カンパニー 鋳型化された金属酸化物粒子及び製造方法
JP4705695B2 (ja) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼb阻害剤としてのピロロ[2,3−d]ピリミジン誘導体
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
PL2694056T3 (pl) 2011-04-01 2020-03-31 Astrazeneca Ab Leczenie terapeutyczne
EP2785349B2 (fr) 2011-11-30 2022-11-09 Astrazeneca AB Nouveau traitement combiné du cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
JP7376358B2 (ja) * 2017-03-12 2023-11-08 ワン,シャオドン オピオイド受容体調節因子としての多環式アミン
WO2019088095A1 (fr) * 2017-11-02 2019-05-09 国立大学法人九州大学 Analgésique et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232138A1 (fr) 1995-09-29 1997-04-03 William C. Lumma Antagonistes du recepteur adrenergique alpha 1b
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
AR032475A1 (es) 2003-11-12
WO2002018348A2 (fr) 2002-03-07
CA2420177A1 (fr) 2002-03-07
AU2001293788B2 (en) 2007-10-11
CA2420177C (fr) 2008-07-08
EP1315714B1 (fr) 2005-11-09
DE60114852D1 (de) 2005-12-15
ATE309240T1 (de) 2005-11-15
PE20020407A1 (es) 2002-05-21
BR0113585A (pt) 2003-07-29
JP2004507527A (ja) 2004-03-11
EP1315714A2 (fr) 2003-06-04
GT200100181A (es) 2002-05-23
PA8527901A1 (es) 2002-07-30
AU9378801A (en) 2002-03-13
CN1308324C (zh) 2007-04-04
ES2251512T3 (es) 2006-05-01
UY26919A1 (es) 2002-02-28
DE60114852T2 (de) 2006-07-27
US20020045614A1 (en) 2002-04-18
MXPA03001777A (es) 2003-06-04
US6559153B2 (en) 2003-05-06
JP3971299B2 (ja) 2007-09-05
CN1545510A (zh) 2004-11-10
WO2002018348A3 (fr) 2002-07-11
KR100602929B1 (ko) 2006-07-20
KR20030022421A (ko) 2003-03-15

Similar Documents

Publication Publication Date Title
US6559153B2 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
AU2001293788A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
EP1363899B1 (fr) Derives quinazolone antagonistes de recepteur alpha 1a/b adrenergique
EP1112270B1 (fr) Dihydrobenzodioxine carboxamide et derives de cetone utilises comme antagonistes du recepteur 5-ht4
EP1058680B1 (fr) Derives de 2-arylethyl-(piperidin-4-ylmethyl)amines
EP1289964A1 (fr) 1-aminoalkyle-lactames substitues et leur utilisation en tant qu'antagonistes de recepteur muscarinique
WO2000055143A1 (fr) Derives d'oxazolone et utilisations de ces derniers en tant que modulateurs du recepteur adrenergique alpha-1
US6864266B2 (en) 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
JP2009513502A (ja) アリールアミン置換キナゾリノン化合物
EP1453806B1 (fr) Derives d'aminotetraline utilises comme antagonistes des recepteurs muscariniques
US6258819B1 (en) Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
US6355641B1 (en) Oxazolone derivatives and uses thereof
JP2009513504A (ja) 5−置換キナゾリノン誘導体
US7091200B2 (en) Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6645971B1 (en) Quinazolinone derivatives
US7226925B2 (en) Compounds, their use and preparation
CZ20003121A3 (cs) 2-Arylethyl-(piperidin-4-ylmethyl)aminové deriváty jako antagonisty muskarinového receptoru